Cargando…

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation

Avapritinib is a protein kinase inhibitor designed to selectively inhibit oncogenic KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase. On 24 September 2020, a marketing authorisation valid through the European Union was issued f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trullas-Jimeno, A., Delgado, J., Garcia-Ochoa, B., Wang, I., Sancho-Lopez, A., Payares-Herrera, C., Dalhus, M.L., Strøm, B.O., Egeland, E.J., Enzmann, H., Pignatti, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165402/ https://www.ncbi.nlm.nih.gov/pubmed/34023541 http://dx.doi.org/10.1016/j.esmoop.2021.100159

Ejemplares similares

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
por: Jones, Robin L., et al.
Publicado: (2021)

The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST)
por: Rizzo, Alessandro, et al.
Publicado: (2021)

The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy
por: Trullas, A., et al.
Publicado: (2021)

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
por: von Mehren, Margaret, et al.
Publicado: (2021)

Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene
por: Indio, Valentina, et al.
Publicado: (2018)

ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report
por: Fan, Jun, et al.
Publicado: (2020)

Long-term response to pimitespib in postoperative recurrent gastrointestinal stromal tumors with PDGFRA D842V mutation: a case report
por: Teranishi, Ryugo, et al.
Publicado: (2023)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS
por: Chi, Susan, et al.
Publicado: (2021)

TRLS-10. ROVER: A PHASE 1/2 STUDY OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING
por: Koschmann, Carl, et al.
Publicado: (2023)

Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan
por: Proudman, David, et al.
Publicado: (2020)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation
por: Indio, Valentina, et al.
Publicado: (2020)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
por: Joseph, Cissimol P., et al.
Publicado: (2021)

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment
por: Ye, Shuai, et al.
Publicado: (2021)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Photosensitivity From Avapritinib: Pharamacovigilance Analysis
por: Venkatakrishnan, Ajit, et al.
Publicado: (2022)

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Avapritinib-induced photo-aggravated cutaneous reaction
por: Dadrass, Farinoosh, et al.
Publicado: (2022)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
por: Sun, Yingchao, et al.
Publicado: (2022)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Successful treatment with avapritinib in patient with mucosal metastatic melanoma
por: Cocorocchio, Emilia, et al.
Publicado: (2020)

Palpable purpuric eruption mimicking vasculitis following avapritinib
por: Mohammed, Taha Osman, et al.
Publicado: (2022)

Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors
por: Jung, Sung Hee, et al.
Publicado: (2011)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

Metanephric stromal tumor in an adult with PDGFRA mutation: a case report
por: Guo, Sanjun, et al.
Publicado: (2023)

Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India
por: Verma, Saurav, et al.
Publicado: (2021)

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
por: Ip, Carman K. M., et al.
Publicado: (2018)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements
por: Delgado, J., et al.
Publicado: (2021)

Abrupt onset of severe parkinsonism in a patient with metastatic gastrointestinal stromal tumor receiving treatment with avapritinib: A case report()
por: Drom, Claire, et al.
Publicado: (2022)

POS-842 EXTRAPOLATION OF BURDEN OF ACUTE KIDNEY INJURY IN HOSPITALISED COVID-19 PATIENTS
por: ARUL ARUMUGAM, P., et al.
Publicado: (2022)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0hbms759nprvqqphkrqhnoos6t